Vaxcyte (PCVX) Equity Ratio (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Equity Ratio data on file, last reported at 0.89 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.89, down 5.54% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.89 (down 5.54% YoY), and the FY2025 annual result was 0.89, down 5.0% from the prior year.
• Equity Ratio was little changed at 0.89 in Q1 2026 per PCVX's latest filing, from 0.89 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.96 in Q3 2024 and troughed at 0.87 in Q3 2022.
• A 5-year average of 0.92 and a median of 0.94 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio gained 8.23% in 2022, then retreated 7.04% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.95 in 2022, then dropped by 7.04% to 0.88 in 2023, then grew by 6.86% to 0.94 in 2024, then slipped by 5.0% to 0.89 in 2025, then increased by 0.05% to 0.89 in 2026.
• Business Quant data shows PCVX's Equity Ratio at 0.89 in Q1 2026, 0.89 in Q4 2025, and 0.91 in Q3 2025.